Literature DB >> 9874796

The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.

N Takeda1, M Shibuya, Y Maru.   

Abstract

The previously uncharacterized CDC24 homology domain of BCR, which is missing in the P185 BCR-ABL oncogene of Philadelphia chromosome (Ph1)-positive acute lymphocytic leukemia but is retained in P210 BCR-ABL of chronic myelogeneous leukemia, was found to bind to the xeroderma pigmentosum group B protein (XPB). The binding appeared to be required for XPB to be tyrosine-phosphorylated by BCR-ABL. The interaction not only reduced both the ATPase and the helicase activities of XPB purified in the baculovirus system but also impaired XPB-mediated cross-complementation of the repair deficiency in rodent UV-sensitive mutants of group 3. The persistent dysfunction of XPB may in part underlie genomic instability in blastic crisis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9874796      PMCID: PMC15117          DOI: 10.1073/pnas.96.1.203

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  An improved assay for nanomole amounts of inorganic phosphate.

Authors:  P A Lanzetta; L J Alvarez; P S Reinach; O A Candia
Journal:  Anal Biochem       Date:  1979-11-15       Impact factor: 3.365

2.  Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)

Authors:  F Pane; F Frigeri; M Sindona; L Luciano; F Ferrara; R Cimino; G Meloni; G Saglio; F Salvatore; B Rotoli
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

Review 3.  TFIIH: a key component in multiple DNA transactions.

Authors:  J H Hoeijmakers; J M Egly; W Vermeulen
Journal:  Curr Opin Genet Dev       Date:  1996-02       Impact factor: 5.578

4.  Typical chronic myelogenous leukemia with e19a2 junction BCR/ABL transcript.

Authors:  M Briz; C Vilches; R Cabrera; R Forés; M N Fernández
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

Review 5.  Chronic myelogenous leukemia: recent advances.

Authors:  R E Champlin; D W Golde
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

6.  Baculovirus expression of functional P210 BCR-ABL oncogene product.

Authors:  A M Pendergast; R Clark; E S Kawasaki; F P McCormick; O N Witte
Journal:  Oncogene       Date:  1989-06       Impact factor: 9.867

7.  Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.

Authors:  G P Amarante-Mendes; C Naekyung Kim; L Liu; Y Huang; C L Perkins; D R Green; K Bhalla
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

8.  Establishment and characterization of a cell line, TOM-1, derived from a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  M Okabe; S Matsushima; M Morioka; M Kobayashi; S Abe; K Sakurada; M Kakinuma; T Miyazaki
Journal:  Blood       Date:  1987-04       Impact factor: 22.113

9.  A 3' --> 5' XPB helicase defect in repair/transcription factor TFIIH of xeroderma pigmentosum group B affects both DNA repair and transcription.

Authors:  J R Hwang; V Moncollin; W Vermeulen; T Seroz; H van Vuuren; J H Hoeijmakers; J M Egly
Journal:  J Biol Chem       Date:  1996-07-05       Impact factor: 5.157

10.  Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia.

Authors:  A LeMaistre; M S Lee; M Talpaz; H M Kantarjian; E J Freireich; A B Deisseroth; J M Trujillo; S A Stass
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

View more
  8 in total

1.  XPB induces C1D expression to counteract UV-induced apoptosis.

Authors:  Guang Li; Juhong Liu; Mones Abu-Asab; Shibuya Masabumi; Yoshiro Maru
Journal:  Mol Cancer Res       Date:  2010-06-08       Impact factor: 5.852

2.  Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia.

Authors:  Jee Hyun Kong; Yeung-Chul Mun; Seonwoo Kim; Hang Seok Choi; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Joon Ho Moon; Sang Kyun Sohn; Sung-Hyun Kim; Chul Won Jung; Dong Hwan Dennis Kim
Journal:  Int J Hematol       Date:  2012-07-21       Impact factor: 2.490

Review 3.  BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

Authors:  B A Burke; M Carroll
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

Review 4.  Molecular biology of chronic myeloid leukemia.

Authors:  Y Maru
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

5.  The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.

Authors:  S Sahay; N L Pannucci; G M Mahon; P L Rodriguez; N J Megjugorac; E V Kostenko; H L Ozer; I P Whitehead
Journal:  Oncogene       Date:  2007-10-08       Impact factor: 9.867

6.  Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity.

Authors:  N L Pannucci; D Li; S Sahay; E K Thomas; R Chen; I Tala; T Hu; B T Ciccarelli; N J Megjugorac; H C Adams Iii; P L Rodriguez; E R Fitzpatrick; D Lagunoff; D A Williams; I P Whitehead
Journal:  Blood Cancer J       Date:  2013-08-16       Impact factor: 11.037

Review 7.  Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors.

Authors:  Shaoguang Li; Dongguang Li
Journal:  J Cell Mol Med       Date:  2007 Nov-Dec       Impact factor: 5.310

Review 8.  Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.

Authors:  Abdulaziz B Hamid; Ruben C Petreaca
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.